ENVB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENVB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Enveric Biosciences's EBITDA per Share for the three months ended in Sep. 2024 was $-3.45.
During the past 3 years, the average EBITDA Per Share Growth Rate was 46.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 53.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Enveric Biosciences was 55.20% per year. The lowest was 36.20% per year. And the median was 46.00% per year.
For the Biotechnology subindustry, Enveric Biosciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Enveric Biosciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Enveric Biosciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Enveric Biosciences (NAS:ENVB) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Thank you for viewing the detailed overview of Enveric Biosciences's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Frank Pasqualone | director | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Kevin Michael Coveney | officer: Chief Financial Officer | 10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606 |
Robert Iv Dickey | officer: Chief Financial Officer | 320 WEST MERMAID LANE, PHILADELPHIA PA 19118 |
Bevin O'neil | director | C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103 |
Michael D Webb | director | C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142 |
Bradley George Thompson | director | 1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9 |
Jillian Marie Hagel | officer: Chief Technical Officer | 3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8 |
Joseph Edward Tucker | director, officer: Chief Executive Officer | 3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8 |
Peter J. Facchini | officer: Chief Scientific Officer | 155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1 |
Carter Julian Ward | officer: Chief Financial Officer | 165 LUDLOW AVE., NORTHVALE NJ 07647 |
Douglas Lind | director | |
Marcus Schabacker | director | ONE BAXTER PARKWAY, DEERFIELD IL 60015 |
Solomon Mayer | director | 150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019 |
David Ian Johnson | director, officer: CEO and Chairman | C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022 |
Robert G. Wilkins | officer: Chief Medical Officer | C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103 |
From GuruFocus
By Business Wire • 12-02-2024
By Business Wire • 05-30-2024
By Business Wire • 09-26-2024
By Faizan Farooque • 01-31-2025
By Business Wire • 07-15-2024
By Business Wire • 03-12-2024
By Business Wire • 10-15-2024
By Business Wire • 09-25-2024
By Business Wire • 02-04-2025
By Business Wire • 11-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.